SIGMAR1 and schizophrenia: It was reported that Sig-1R agonists could be used for treating neuropsychiatric disorders through tackling factors like oxidative stress, inflammation, disruptions in Ca2+ balance, and increased production of normal or misfolded proteins that can result in the buildup of unfolded proteins, and eventually, the onset of neuropsychiatric disorders including schizophrenia (Hashimoto 2015).